Skip to content
  • Member Login
Ontario Rheumatology Association
  • Login
  • About
    • Overview
    • Priorities & Committees
    • Leadership
    • Annual Awards
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • RheumView
    • Overview
    • RheumView Main
    • Instructional Videos
    • Getting Started
    • Events
    • FAQs
  • Membership
    • Overview
    • Become A Member
    • Member Dashboard
    • Member Directory
    • Peer Mentor Forum
    • Helpful Links
    • Renew Membership
  • News & Events
    • Overview
    • Annual Scientific Meeting
    • Drug Shortages Info
    • Info Hub
  • Directory
  • Contact
  • Login
  • About
    • Overview
    • Priorities & Committees
    • Leadership
    • Annual Awards
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • RheumView
    • Overview
    • RheumView Main
    • Instructional Videos
    • Getting Started
    • Events
    • FAQs
  • Membership
    • Overview
    • Become A Member
    • Member Dashboard
    • Member Directory
    • Peer Mentor Forum
    • Helpful Links
    • Renew Membership
  • News & Events
    • Overview
    • Annual Scientific Meeting
    • Drug Shortages Info
    • Info Hub
  • Directory
  • Contact

Prior Authorization

Imtiaz Khan • Edition: Winter 2021

The Private Payers Committee gave a brief update on Prior Authorizations at the February 4/21 ORA Town Hall. Uncertainties surround the criteria used to approve/reject prescribed therapeutics and I would ask members to provide redacted rejections along with the dates of application submissions and resolutions (were they successful resubmissions? Was therapy changed?).  Please send examples to admin@ontariorheum.ca. We want to get an estimate of the scope and magnitude and will track this and work towards an appropriate response from the ORA.

Members interested in participating in a subcommittee are welcome!

Other Articles in the Winter 2021 Newsletter

  • President's Message
  • Interview With Ashley Sterrett on ArthritisAtHome
  • Informatics Update on the ORDER Project
  • Government Affairs Committee Update
  • Emerging Rheumatologists of Ontario
  • OMA Section on Rheumatology Report
  • Communications Update
Editions
  • Winter 2021
  • Fall 2020
  • Summer 2020
  • Winter 2020
  • Winter 2019
  • Fall 2019
  • Spring 2019
  • Winter 2018
  • Fall 2018
  • Summer 2018
  • Summer 2017
  • Spring 2017
  • Fall 2017
  • Archive
  • Meet the Speakers: ORA 20th Annual Scientific Meeting
Committees
Communications Informatics Models of Care OMA
Tags
Biosimilar CSDTH Models of Care OBRI OMA pCPA SADIE

Contributors

The ORA’s executive members are the core contributors to the newsletter. The ORA welcomes guest contributions to the newsletter from members-at-large and others in the rheumatology community.

Contributors
Ontario Rheumatology Association
© 2025 Ontario Rheumatology Association. All Rights Reserved. Website by Digital Chaos Inc.

  • About
  • Priorities & Committees
  • Leadership
  • Annual Awards
  • Contact
  • Privacy
  • EAP & Limited Use Codes
  • Exceptional Access Program
  • EAP Forms and Downloads
  • Limited Use Codes
  • Biosimilar Fact Sheet
  • NIHB Drug List
  • MOHLTC IVIG Request Form
  • RheumView
  • Overview
  • Instructional Videos
  • Getting Started
  • Events
  • FAQs
  • Membership
  • Member Directory
  • Past Meeting Resources
  • Peer Mentor Forum
  • Become A Member
  • Renew Membership
  • News & Events
  • ASM 2025
  • Drug Shortages Info
  • Newsletter Archive
  • Publication Archive
  • Info Hub
  • Find a Rheumatologist